These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19855900)

  • 1. Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update.
    Chaves C; Marque CR; Trzesniak C; Machado de Sousa JP; Zuardi AW; Crippa JA; Dursun SM; Hallak JE
    Braz J Med Biol Res; 2009 Nov; 42(11):1002-14. PubMed ID: 19855900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of a novel pharmacotherapy targeted at the N-methyl-D-aspartate receptor-D-serine system for schizophrenia].
    Nishikawa T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):201-6. PubMed ID: 21226316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.
    Tsai GE; Lin PY
    Curr Pharm Des; 2010; 16(5):522-37. PubMed ID: 19909229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D-alanine added to antipsychotics for the treatment of schizophrenia.
    Tsai GE; Yang P; Chang YC; Chong MY
    Biol Psychiatry; 2006 Feb; 59(3):230-4. PubMed ID: 16154544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.
    Shim SS; Hammonds MD; Kee BS
    Eur Arch Psychiatry Clin Neurosci; 2008 Feb; 258(1):16-27. PubMed ID: 17901997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.
    Lindsley CW; Shipe WD; Wolkenberg SE; Theberge CR; Williams DL; Sur C; Kinney GG
    Curr Top Med Chem; 2006; 6(8):771-85. PubMed ID: 16719816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review.
    Millan MJ
    Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):191-213. PubMed ID: 12769627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of NMDA receptors in new treatments for schizophrenia.
    Hashimoto K
    Expert Opin Ther Targets; 2014 Sep; 18(9):1049-63. PubMed ID: 24965576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [NMDA-type glutamate receptor and schizophrenia].
    Nishikawa T; Ishiwata S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):217-24. PubMed ID: 25069261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia].
    Kolomeets NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):110-117. PubMed ID: 25945378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamate signaling in the pathophysiology and therapy of schizophrenia.
    Lin CH; Lane HY; Tsai GE
    Pharmacol Biochem Behav; 2012 Feb; 100(4):665-77. PubMed ID: 21463651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
    Singh SP; Singh V
    CNS Drugs; 2011 Oct; 25(10):859-85. PubMed ID: 21936588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
    Kawaura K; Koike H; Kinoshita K; Kambe D; Kaku A; Karasawa J; Chaki S; Hikichi H
    Behav Brain Res; 2015 Feb; 278():186-92. PubMed ID: 25300471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
    Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
    Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.
    Heresco-Levy U; Javitt DC
    Schizophr Res; 2004 Feb; 66(2-3):89-96. PubMed ID: 15061240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Pharmacological Targets for the Treatment of Schizophrenia: A Literature Review.
    Ventriglio A; Bellomo A; Ricci F; Magnifico G; Rinaldi A; Borraccino L; Piccininni C; Cuoco F; Gianfelice G; Fornaro M; Delle Monache S; De Berardis D
    Curr Top Med Chem; 2021 Oct; 21(16):1500-1516. PubMed ID: 34218785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia.
    Coyle JT; Tsai G; Goff D
    Ann N Y Acad Sci; 2003 Nov; 1003():318-27. PubMed ID: 14684455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
    Yang CR; Svensson KA
    Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.